BiomX Inc

BiomX Inc operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company's liquidity position is characterized by a current ratio of 4.4, indicating a strong short-term liquidity buffer relative to its liabilities. However, the company's valuation is extremely low, with a price-to-book ratio of 0.26, suggesting that the market capitalization is significantly below the book value of its equity. The company's market cap of approximately $5.9 million is also indicative of a small-cap, early-stage biotechnology firm.

Profitability metrics for BiomX are negative, with a return on equity of -75.74% and a return on assets of -21.23%, both of which are well below the typical performance of firms in the biotechnology industry. The company reported a net loss of $17.3 million and an operating loss of $6.8 million in the latest period. These figures suggest that the company is not yet generating positive returns for shareholders and is likely in the research and development phase of its business model.

The company's revenue concentration is not disclosed in the available data, but as a biotechnology firm, it is likely that its revenue is derived from a limited number of products or partnerships. The absence of capital expenditures and the lack of long-term debt suggest that the company is not currently investing in physical assets or expanding its operations through traditional means. Instead, the company is likely allocating resources to research and development, which is a common strategy for firms in the biotechnology sector.

Looking ahead, the company's growth trajectory is uncertain, as it has not provided specific revenue guidance for the current or next fiscal year. Analysts have assigned a mean recommendation of 2.50, which is a "Hold" rating, with one "Buy" and one "Hold" recommendation. The lack of strong buy or sell ratings suggests that the market is cautious about the company's prospects. The company's recent financial performance, including a net loss of $17.3 million and an operating loss of $6.8 million, indicates that it is not yet profitable and may require additional capital to fund its operations.

The risk assessment for BiomX Inc indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, which suggests that it is not currently facing significant financial distress. However, the company's negative net income and operating cash flow indicate that it may need to raise additional capital in the future to continue its operations. The absence of long-term debt and the presence of a strong current ratio suggest that the company has some flexibility in managing its short-term obligations.

Recent events related to BiomX Inc include the latest financial results, which show a continued net loss and operating loss. The company has not disclosed any recent filings or transcripts that would provide additional insight into its operations or strategic direction. The lack of recent events may indicate that the company is in a stable but uneventful phase of its development.

Operating income −6,3% YoY; Net income +8,1% YoY.

• ▍Operating income −6,3% YoY
• ▍Net income +8,1% YoY
• ▍Free cash flow +10,4% YoY

Operating income +24,6% YoY; Net income −195,1% YoY.

• ▍Operating income +24,6% YoY
• ▍Net income −195,1% YoY
• ▍Free cash flow −179,6% YoY

Operating income +23,6% YoY; Net income −235,0% YoY.

• ▍Operating income +23,6% YoY
• ▍Net income −235,0% YoY
• ▍Free cash flow −219,9% YoY

Operating income −14,3% YoY; Net income +55,8% YoY.

• ▍Operating income −14,3% YoY
• ▍Net income +55,8% YoY
• ▍Free cash flow +56,6% YoY

Operating income -$16.7M.

• ▍Operating income -$16.7M

Operating income +6,9% YoY; Net income −104,2% YoY.

• ▍Operating income +6,9% YoY
• ▍Net income −104,2% YoY
• ▍Free cash flow −108,6% YoY

Operating income −75,7% YoY; Net income +32,3% YoY.

• ▍Operating income −75,7% YoY
• ▍Net income +32,3% YoY
• ▍Free cash flow +37,1% YoY